Andere talen TransCode Therapeutics, Inc.

Aandelen

RNAZ

US89357L3033

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,5499 ^USD	+4,74%		+13,38%	-91,66%

15/04	TransCode Therapeutics, Inc. kondigt goedkeuring van de FDA aan voor het starten van een Fase 1/2 klinische studie metttx-Mc138 bij patiënten met gevorderde vaste tumoren	CI
01/04	TransCode Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

TransCode Therapeutics : Shareholder Meeting - Form 8-K	23/04
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22/04
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22/04
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22/04
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors	15/04
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors	15/04
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors	15/04
TransCode Therapeutics Reports 2023 Results; Provides Business Update	03/04
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28/03
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28/03
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11/03
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11/03
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic	20/02
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode?s RIG-I Agonist Immunotherapeutic	20/02
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market	31/01
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer	29/01
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	29/01
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	29/01
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering	22/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen TransCode Therapeutics, Inc.

Aandelen

RNAZ

US89357L3033

Andere talen

Filters